<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D61BD3A3-810B-43CE-8C99-BF7A4BB4BC3A"><gtr:id>D61BD3A3-810B-43CE-8C99-BF7A4BB4BC3A</gtr:id><gtr:name>Cellcentric Limited</gtr:name><gtr:address><gtr:line1>CHESTERFORD RESEARCH PARK , LITTLE CHESTERFORD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D61BD3A3-810B-43CE-8C99-BF7A4BB4BC3A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>D61BD3A3-810B-43CE-8C99-BF7A4BB4BC3A</gtr:id><gtr:name>Cellcentric Limited</gtr:name><gtr:address><gtr:line1>CHESTERFORD RESEARCH PARK , LITTLE CHESTERFORD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>126000.0</gtr:offerGrant><gtr:projectCost>180000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/253D636A-3C58-43BD-8A34-5688CF7D1BCC"><gtr:id>253D636A-3C58-43BD-8A34-5688CF7D1BCC</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=132659"><gtr:id>3E9D11E4-ACCB-41E4-8340-90D0D3571D6E</gtr:id><gtr:title>A new application for a novel drug candidate - in lung cancer</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>132659</gtr:grantReference><gtr:abstractText>1 in 4 cancer deaths in men and women are a result of lung cancer. Despite significant advances in recent years, both in terms of early detection and novel therapies, there remains a significant unmet need for cost-effective drugs that offer long term benefits. CellCentric has developed a novel, highly potent potential drug for the aggressive form of prostate cancer, that is expected to be taken orally 1-2 times a day. This is advancing to clinical trials. Recent studies reported in the literature by others (Jan-Mar 2016) have unexpectedly, indicated that CellCentric's drug could have specific application for 10-15% of patients who have non-small cell and small cell lung cancers. These tumours are readily identifiable with existing bioassays. The patients, particularly in the advanced stages, have few alternatives. This project will use tests involving cells and human tumour tissues to seek to extend some of the findings reported by others, and confirm whether CellCentric's easy to administer drug could be used beyond prostate cancer, for lung cancer too. Even a 10-15% lung cancer opportunity represents a significant patient population, that would derive meaningful clinical benefit from such an approach.</gtr:abstractText><gtr:fund><gtr:end>2017-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>126000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">132659</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>